Wells Fargo Turns Bullish on Alector, Citing Overlooked Brain Delivery Technology

Wells Fargo initiates Alector with an Overweight rating and $7 price target, citing its brain carrier platform and Alzheimer’s drug AL-137.

Wells Fargo Turns Bullish on Alector, Citing Overlooked Brain Delivery Technology
Credit: Alector
Already have an account? Sign in.